Cicor Technologies (CICN) Investor presentation summary

Market positioning and business focus

• Ranked fourth among EMS companies in Europe, with a strong presence in industrial, healthcare technology, and aerospace & defence sectors, addressing a €21.4 billion market with a 5.6% CAGR forecast for 2024-2027.

• 2025 sales distribution: 38% industrial, 26% aerospace & defence, 19% healthcare technology.

• Offers interdisciplinary engineering, advanced manufacturing, and sophisticated substrate production for demanding applications.

Financial performance and growth

• 2025 sales reached CHF 616.5 million, up 28.2% year-over-year, with adjusted EBITDA of CHF 64.6 million (10.5% margin) and free cash flow of CHF 49.1 million.

• Adjusted net profit for 2025 was CHF 32.7 million, with earnings per share at CHF 7.45.

• Employee count grew to 4,524 FTEs by year-end 2025.

• Book-to-bill ratio improved to 1.05, and free cash flow conversion was 87%.

• Share price more than doubled to CHF 127.00, with market capitalization at CHF 558.8 million.

Strategic expansion and M&A activity

• Expanded manufacturing and engineering footprint to 7 markets, accessing over 70% of European electronics OEMs.

• Completed major acquisitions in 2025: Éolane (France, Morocco), Mercury Systems (Switzerland), MADES (Spain), Valtronic (Morocco, USA), and Profectus Solutions (Germany).

• M&A strategy focused on strengthening positions in aerospace & defence, healthcare technology, and industrial electronics.

• Integration of five acquired companies is a key priority for 2026.